A Netflix executive is suing the company, alleging he is fired after disclosing that he used prescribed ketamine. According to the lawsuit reported by NDTV, the executive, whose name is Baillie, sought ketamine therapy at a clinic in Santa Barbara in late 2022. The filing says he pursued the treatment after struggling with clinical depression following the death of his mother. The claim centers on whether Netflix took adverse action after he disclosed his medical use of ketamine, which is presented in the lawsuit as prescribed treatment. The sources provided do not include Netflix’s response or additional details about internal policies, the timeline of any disclosure, or the reasons stated by the company for the termination. The suit therefore focuses on the alleged connection between the disclosure of medical ketamine and the employment decision. The reports do not specify the remedy sought, the court where the case is filed, or whether any evidence beyond the described treatment is referenced in the complaint.